

Javier P Gisbert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8181711/publications.pdf>

Version: 2024-02-01

449
papers

28,071
citations

4942

84
h-index

8138

148
g-index

526
all docs

526
docs citations

526
times ranked

16684
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of <i>Helicobacter pylori</i> infection – the Maastricht V/Florence Consensus Report. <i>Gut</i> , 2017, 66, 6-30.	6.1	2,245
2	Management of <i>Helicobacter pylori</i> infection – the Maastricht IV/ Florence Consensus Report. <i>Gut</i> , 2012, 61, 646-664.	6.1	2,023
3	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
4	The Toronto Consensus for the Treatment of <i>Helicobacter pylori</i> Infection in Adults. <i>Gastroenterology</i> , 2016, 151, 51-69.e14.	0.6	671
5	Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review. <i>American Journal of Gastroenterology</i> , 2009, 104, 760-767.	0.2	564
6	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1909-1915.	6.3	517
7	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
8	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 211-222.	0.6	425
9	Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 847-858.e4.	2.4	322
10	Review article: 13 C-urea breath test in the diagnosis of <i>Helicobacter pylori</i> infection - a critical review. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1001-1017.	1.9	305
11	Systematic review and meta-analysis: levofloxacin-based rescue regimens after <i>Helicobacter pylori</i> treatment failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 35-44.	1.9	296
12	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 2-17.	0.6	288
13	Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 613-623.	1.9	266
14	Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1190-1198.	0.9	265
15	Accuracy of Monoclonal Stool Antigen Test for the Diagnosis of <i>H. pylori</i> Infection: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2006, 101, 1921-1930.	0.2	250
16	Safety of Thiopurine Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1404-1410.	0.9	243
17	Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review. <i>American Journal of Gastroenterology</i> , 2008, 103, 1783-1800.	0.2	223
18	Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 645-659.	1.9	219

#	ARTICLE	IF	CITATIONS
19	A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 603-609.	1.9	213
20	Meta-analysis: role of <i>Helicobacter pylori</i> eradication in the prevention of peptic ulcer in NSAID users. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1411-1418.	1.9	201
21	Safety of Thiopurines and Anti-TNF- α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, 433-440.	0.2	197
22	Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2009, 41, 56-66.	0.4	195
23	Sequential Therapy for <i>Helicobacter pylori</i> Eradication. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 313-325.	1.1	194
24	Common Misconceptions in the Diagnosis and Management of Anemia in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 1299-1307.	0.2	191
25	<i>Helicobacter pylori</i> "rescue" regimen when proton pump inhibitor-based triple therapies fail. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1047-1057.	1.9	190
26	Accuracy of <i>Helicobacter pylori</i> Diagnostic Tests in Patients with Bleeding Peptic Ulcer: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2006, 101, 848-863.	0.2	190
27	5-Aminosalicylates and renal function in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 629-638.	0.9	186
28	Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 126-137.	1.9	186
29	Thiopurine-Induced Liver Injury in Patients With Inflammatory Bowel Disease: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2007, 102, 1518-1527.	0.2	182
30	Optimized Nonbismuth Quadruple Therapies Cure Most Patients With <i>Helicobacter pylori</i> Infection in Populations With High Rates of Antibiotic Resistance. <i>Gastroenterology</i> , 2013, 145, 121-128.e1.	0.6	177
31	Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 414-425.	1.9	165
32	Anemia and inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2009, 15, 4659.	1.4	162
33	Review article: rifabutin in the treatment of refractory <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 209-221.	1.9	161
34	Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of <i>Helicobacter pylori</i> . <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1319-1328.	1.9	159
35	The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2016, 111, 632-647.	0.2	156
36	European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal [Exit Strategies] in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 17-31.	0.6	151

#	ARTICLE	IF	CITATIONS
37	Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 694-709.	0.6	148
38	Ustekinumab for the Treatment of Refractory Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1662-1669.	0.9	146
39	Review article: non-bismuth quadruple (concomitant) therapy for eradication of <i>Helicobacter pylori</i> . <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 604-617.	1.9	145
40	Selective Manipulation of the Gut Microbiota Improves Immune Status in Vertebrates. <i>Frontiers in Immunology</i> , 2015, 6, 512.	2.2	145
41	Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2003, 39, 620-627.	1.8	144
42	Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and -22 Production and Promotes Intestinal Barrier Integrity. <i>Immunity</i> , 2019, 50, 446-461.e9.	6.6	143
43	Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 144-152.	0.6	139
44	European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21,533 patients. <i>Gut</i> , 2021, 70, 40-54.	6.1	139
45	Long-Term Safety of In Utero Exposure to Anti-TNF α Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>American Journal of Gastroenterology</i> , 2018, 113, 396-403.	0.2	134
46	Systematic review with meta-analysis: inflammatory bowel disease in the elderly. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 459-477.	1.9	129
47	<i>Helicobacter pylori</i> eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 617-629.	1.9	127
48	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1430-1439.	0.6	123
49	Efficacy of Hepatitis B Vaccination and Revaccination and Factors Impacting on Response in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 1460-1466.	0.2	121
50	Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 881-895.	0.9	120
51	Optimum duration of regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2013, , CD008337.	1.5	120
52	Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for <i>Helicobacter pylori</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2447-2455.	1.3	120
53	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 179-189.	0.6	120
54	Randomised clinical trial comparing sequential and concomitant therapies for <i>Helicobacter pylori</i> eradication in routine clinical practice. <i>Gut</i> , 2014, 63, 244-249.	6.1	119

#	ARTICLE	IF	CITATIONS
55	Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. <i>Gut</i> , 2018, 67, 237-243.	6.1	119
56	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2026-2033.	0.9	118
57	Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1485-1491.	0.9	114
58	Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose "Escalation" in Patients Losing Response. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 113-118.	1.1	114
59	Review article: the effectiveness of standard triple therapy for <i>Helicobacter pylori</i> has not changed over the last decade, but it is not good enough. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1255-1268.	1.9	114
60	Update on non-bismuth quadruple (concomitant) therapy for eradication of <i>Helicobacter pylori</i> . <i>Clinical and Experimental Gastroenterology</i> , 2012, 5, 23.	1.0	114
61	Systematic review: gastric microbiota in health and disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 582-602.	1.9	113
62	Single vs. double dose of a proton pump inhibitor in triple therapy for <i>Helicobacter pylori</i> eradication: a meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1149-1156.	1.9	112
63	Thiopurine Methyltransferase (TPMT) Activity and Adverse Effects of Azathioprine in Inflammatory Bowel Disease: Long-Term Follow-Up Study of 394 Patients. <i>American Journal of Gastroenterology</i> , 2006, 101, 2769-2776.	0.2	110
64	Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 868-877.	1.9	110
65	Review article: <i>Helicobacter pylori</i> -negative duodenal ulcer disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 791-815.	1.9	108
66	Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, 1426-1438.	0.2	105
67	Human intestinal pro-inflammatory CD11c ^{high} CCR2 ⁺ CX3CR1 ⁺ macrophages, but not their tolerogenic CD11c ^{low} CCR2 ⁺ CX3CR1 ⁺ counterparts, are expanded in inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018, 11, 1114-1126.	2.7	105
68	The Stool Antigen Test for Detection of <i>Helicobacter pylori</i> after Eradication Therapy. <i>Annals of Internal Medicine</i> , 2002, 136, 280.	2.0	104
69	Liver injury in inflammatory bowel disease: Long-term follow-up study of 786 patients. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1106-1114.	0.9	103
70	Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 275-283.	1.9	102
71	Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 619-633.	1.9	101
72	<i>Helicobacter pylori</i> "Rescue" Therapy After Failure of Two Eradication Treatments. <i>Helicobacter</i> , 2005, 10, 363-372.	1.6	99

#	ARTICLE	IF	CITATIONS
73	Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 391-405.	1.9	99
74	Third-Line Rescue Therapy with Levofloxacin After Two H. pylori Treatment Failures. <i>American Journal of Gastroenterology</i> , 2006, 101, 243-247.	0.2	98
75	'Rescue' regimens after Helicobacter pylori treatment failure. <i>World Journal of Gastroenterology</i> , 2008, 14, 5385.	1.4	98
76	'Rescue' Therapy with Rifabutin after Multiple Helicobacter pylori Treatment Failures. <i>Helicobacter</i> , 2003, 8, 90-94.	1.6	97
77	IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. <i>Gastroenterología Y Hepatología</i> , 2016, 39, 697-721.	0.2	97
78	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2016, 14, 133.	2.3	97
79	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 120-131.	0.2	93
80	Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 340-348.	1.9	92
81	Systematic review: antibodies and anti-TNF levels in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 971-986.	1.9	91
82	Helicobacter pylori second-line rescue therapy with levofloxacin and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 768-775.	1.9	91
83	Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. <i>International Journal of Cancer</i> , 2013, 133, 1023-1032.	2.3	90
84	Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 240-251.	0.6	89
85	Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. <i>Gastroenterology</i> , 2021, 161, 495-507.e4.	0.6	89
86	Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 953-958.	1.4	87
87	Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. <i>Microorganisms</i> , 2021, 9, 977.	1.6	83
88	Thiopurine Methyltransferase Activity in Spain: A Study of 14,545 Patients. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1262-1269.	1.1	82
89	Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1469-1474.	1.9	81
90	Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 717-722.	0.6	80

#	ARTICLE	IF	CITATIONS
91	Epidemiological risk factors in microscopic colitis: a prospective case-control study. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 411-7.	0.9	80
92	Second-Line Rescue Therapy With Levofloxacin After <i>H. pylori</i> Treatment Failure: A Spanish Multicenter Study of 300 Patients. <i>American Journal of Gastroenterology</i> , 2008, 103, 71-76.	0.2	79
93	Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible <i>Helicobacter pylori</i> and versus Sequential Therapy for Clarithromycin-Resistant Strains. <i>Helicobacter</i> , 2012, 17, 269-276.	1.6	79
94	Seven-day "rescue"™ therapy after <i>Helicobacter pylori</i> treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1311-1316.	1.9	78
95	Empirical rescue therapy after <i>Helicobacter pylori</i> treatment failure: a 10-year single-centre study of 500 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 346-354.	1.9	77
96	Evolution of <i>Helicobacter pylori</i> Therapy from a Meta-analytical Perspective. <i>Helicobacter</i> , 2007, 12, 50-58.	1.6	77
97	Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1379-1385.	1.9	77
98	Triple vs. quadruple therapy for treating <i>Helicobacter pylori</i> infection: an updated meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 543-544.	1.9	76
99	The association between <i>Helicobacter pylori</i> infection and inflammatory bowel disease based on meta-analysis. <i>United European Gastroenterology Journal</i> , 2015, 3, 539-550.	1.6	76
100	A review of rescue regimens after clarithromycin-containing triple therapy failure (for <i>Helicobacter</i>)	0.9	73
101	Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 752-760.	1.9	73
102	Has <i>H. pylori</i> Prevalence in Bleeding Peptic Ulcer Been Underestimated? A Meta-Regression. <i>American Journal of Gastroenterology</i> , 2011, 106, 398-405.	0.2	72
103	Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. <i>EBioMedicine</i> , 2019, 48, 648-655.	2.7	72
104	Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1394-1402.	0.9	71
105	Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 839-851.	1.9	71
106	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. <i>Cell Host and Microbe</i> , 2021, 29, 1573-1588.e7.	5.1	71
107	Optimised empiric triple and concomitant therapy for <i>Helicobacter pylori</i> eradication in clinical practice: the OPTRICON study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 581-589.	1.9	70
108	Optimization strategies aimed to increase the efficacy of <i>H. pylori</i> eradication therapies. <i>Helicobacter</i> , 2017, 22, e12392.	1.6	69

#	ARTICLE	IF	CITATIONS
109	Long-Term Follow-Up of 1,000 Patients Cured of <i>Helicobacter pylori</i> Infection Following an Episode of Peptic Ulcer Bleeding. <i>American Journal of Gastroenterology</i> , 2012, 107, 1197-1204.	0.2	64
110	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <i>Digestive Diseases</i> , 2019, 37, 266-283.	0.8	63
111	Combination of Bismuth and Standard Triple Therapy Eradicates <i>Helicobacter pylori</i> Infection in More than 90% of Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 89-98.	2.4	62
112	Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 130-135.	1.1	60
113	Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 90.	1.0	59
114	Review article: common misconceptions in the management of <i>Helicobacter pylori</i> -associated gastric MALT-lymphoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1047-1062.	1.9	59
115	Optimizing clarithromycin-containing therapy for <i>Helicobacter pylori</i> in the era of antibiotic resistance. <i>World Journal of Gastroenterology</i> , 2014, 20, 10338.	1.4	59
116	Effectiveness of Adalimumab in Perianal Fistulas in Crohn's Disease Patients Naive to Anti-TNF Therapy. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 34-40.	1.1	59
117	Empirical or susceptibility-guided treatment for <i>Helicobacter pylori</i> infection? A comprehensive review. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096873.	1.4	58
118	Fourth-line rescue therapy with rifabutin in patients with three <i>Helicobacter pylori</i> eradication failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 941-947.	1.9	57
119	Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 605-614.	1.9	57
120	Meta-analysis of three single capsule bismuth-containing quadruple therapy for the eradication of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2019, 24, e12570.	1.6	57
121	Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 35-42.	0.6	57
122	<i>Helicobacter pylori</i> first-line treatment and rescue options in patients allergic to penicillin. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 1041-1046.	1.9	56
123	Role of food proteins and bioactive peptides in inflammatory bowel disease. <i>Trends in Food Science and Technology</i> , 2019, 88, 194-206.	7.8	55
124	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1037-1048.	0.6	55
125	Impact of Current Smoking on the Clinical Course of Microscopic Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1470-1476.	0.9	54
126	Accuracy of GastroPanel for the diagnosis of atrophic gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 941-948.	0.8	54

#	ARTICLE	IF	CITATIONS
127	Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 400-426.	1.9	54
128	Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. <i>Drugs</i> , 2020, 80, 1085-1100.	4.9	54
129	<i>Helicobacter pylori</i> first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. <i>Digestive and Liver Disease</i> , 2010, 42, 287-290.	0.4	53
130	<i>Helicobacter Pylori</i> "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. <i>Clinical and Translational Gastroenterology</i> , 2013, 4, e32.	1.3	53
131	Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 278-288.	1.9	53
132	Treatment of <i>Helicobacter pylori</i> Infection 2013. <i>Helicobacter</i> , 2013, 18, 58-65.	1.6	52
133	<i>Helicobacter Pylori</i> Infection Does Not Protect Against Eosinophilic Esophagitis: Results From a Large Multicenter Case-Control Study. <i>American Journal of Gastroenterology</i> , 2018, 113, 972-979.	0.2	52
134	Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 996-1002.	0.6	52
135	Recurrence of <i>Helicobacter pylori</i> Infection after Eradication: Incidence and Variables Influencing It. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 1144-1151.	0.6	50
136	Long-term durability of response to adalimumab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 685-690.	0.9	50
137	First-line triple therapy with levofloxacin for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 495-500.	1.9	49
138	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 118-127.	3.7	49
139	Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for <i>H. pylori</i> Infection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 383-389.	1.1	48
140	Antibiotic Resistance Prevalence and Trends in Patients Infected with <i>Helicobacter pylori</i> in the Period 2013-2020: Results of the European Registry on <i>H. pylori</i> Management (Hp-EuReg). <i>Antibiotics</i> , 2021, 10, 1058.	1.5	48
141	Identification of Risk Loci for Crohn's Disease Phenotypes Using a Genome-Wide Association Study. <i>Gastroenterology</i> , 2015, 148, 794-805.	0.6	46
142	Treatment of <i>Helicobacter pylori</i> infection in 2018. <i>Helicobacter</i> , 2018, 23, e12519.	1.6	46
143	Protocol of the European Registry on the management of <i>Helicobacter pylori</i> infection (Hp-EuReg). <i>Helicobacter</i> , 2019, 24, e12630.	1.6	46
144	Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11273.	1.4	46

#	ARTICLE	IF	CITATIONS
145	Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. <i>Human Immunology</i> , 2014, 75, 71-75.	1.2	45
146	Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1529-1538.	0.6	45
147	Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1063-1070.	0.6	45
148	Therapeutic guidelines on ulcerative colitis: A GRADE methodology based effort of GETECCU. <i>Gastroenterología y Hepatología</i> , 2013, 36, 104-114.	0.2	44
149	Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 481-490.	1.1	43
150	Quality of Care Standards in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 127-137.	0.6	43
151	Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy. <i>Digestive Diseases and Sciences</i> , 2015, 60, 458-464.	1.1	42
152	Propionibacterium acnes overabundance and natural killer group 2 member D system activation in corpus-dominant lymphocytic gastritis. <i>Journal of Pathology</i> , 2016, 240, 425-436.	2.1	42
153	Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 261-268.	0.2	42
154	The Innate Immune System in the Gastrointestinal Tract: Role of Intraepithelial Lymphocytes and Lamina Propria Innate Lymphoid Cells in Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1649-1659.	0.9	42
155	Role of partner's infection in reinfection after Helicobacter pylori eradication. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 865-871.	0.8	41
156	Increased risk of thiopurine-related adverse events in elderly patients with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 780-788.	1.9	40
157	Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). <i>American Journal of Gastroenterology</i> , 2021, 116, 1220-1229.	0.2	40
158	Evaluation of three different tests for the detection of stool antigens to diagnose Helicobacter pylori infection in patients with upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 923-929.	1.9	39
159	A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. <i>Human Molecular Genetics</i> , 2014, 23, 6927-6934.	1.4	39
160	European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. <i>United European Gastroenterology Journal</i> , 2021, 9, 38-46.	1.6	39
161	Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1846-1851.	0.6	39
162	Transplacental Transfer of Immunosuppressants and Biologics Used for the Treatment of Inflammatory Bowel Disease. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 765-773.	0.9	39

#	ARTICLE	IF	CITATIONS
163	Health Care Costs of Complex Perianal Fistula in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3400-3406.	1.1	38
164	Kinetics of Anti-Hepatitis B Surface Antigen Titers After Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 554-558.	0.9	38
165	Review: Treatment of <i>Helicobacter pylori</i> Infection 2019. <i>Helicobacter</i> , 2019, 24, e12640.	1.6	38
166	Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2885.	1.0	38
167	Rifabutin for the Treatment of <i>Helicobacter pylori</i> Infection: A Review. <i>Pathogens</i> , 2021, 10, 15.	1.2	38
168	Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 689-692.	0.8	37
169	Treatment of <i>Helicobacter pylori</i> infection 2012. <i>Helicobacter</i> , 2012, 17, 36-42.	1.6	37
170	Intensification of infliximab therapy in Crohn's disease: Efficacy and safety. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 62-67.	0.6	37
171	Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – Multicenter European cohort study. <i>Digestive and Liver Disease</i> , 2016, 48, 592-600.	0.4	37
172	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1492-1500.	0.6	37
173	Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for <i>Helicobacter pylori</i> first-line treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2740-2753.	1.3	36
174	Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 374-384.	0.6	36
175	Room for Improvement in the Treatment of <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e98-e108.	1.1	36
176	The TETRA Study: A prospective evaluation of <i>Helicobacter pylori</i> 'Test-and-Treat' Strategy on 736 Patients in Clinical Practice. <i>Helicobacter</i> , 2004, 9, 28-38.	1.6	35
177	Current Management of Iron Deficiency Anemia in Inflammatory Bowel Diseases: A Practical Guide. <i>Drugs</i> , 2013, 73, 1761-1770.	4.9	35
178	Sequential versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2016, , CD009034.	1.5	35
179	Systematic review: third-line susceptibility-guided treatment for <i>Helicobacter pylori</i> infection. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 437-448.	1.4	35
180	Human Intestinal Dendritic Cells in Inflammatory Bowel Diseases. <i>Molecular Nutrition and Food Research</i> , 2018, 62, e1700931.	1.5	35

#	ARTICLE	IF	CITATIONS
181	A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent <i>Clostridium difficile</i> infection. United European Gastroenterology Journal, 2019, 7, 1051-1063.	1.6	35
182	The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. International Journal of Molecular Sciences, 2021, 22, 3076.	1.8	35
183	Rabeprazole-based therapies in Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 2003, 17, 751-764.	1.9	34
184	Esomeprazole-Based Therapy in Helicobacter pylori Eradication: Any Effect by Increasing the Dose of Esomeprazole or Prolonging the Treatment?. American Journal of Gastroenterology, 2005, 100, 1935-1940.	0.2	34
185	Rescue Therapy for <i>Helicobacter pylori</i> Infection 2012. Gastroenterology Research and Practice, 2012, 2012, 1-12.	0.7	34
186	Treatment of <i>Helicobacter pylori</i> Infection 2015. Helicobacter, 2015, 20, 54-61.	1.6	34
187	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de tiopurinas en la enfermedad inflamatoria intestinal. Gastroenterología Y Hepatología, 2018, 41, 205-221.	0.2	34
188	Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for <i>Helicobacter pylori</i> therapy: A randomized, double-blind, placebo-controlled trial. Helicobacter, 2018, 23, e12529.	1.6	34
189	Review "Treatment of <i>Helicobacter pylori</i> infection 2020. Helicobacter, 2020, 25, e12743.	1.6	34
190	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterología Y Hepatología, 2018, 41, 514-529.	0.2	33
191	El registro ENEIDA (Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes) Tj ETQq1 1 0.784314 rgBT /Overlock Hepatología, 2020, 43, 551-558.	0.2	33
192	Endothelial α MT targeting limits intussusceptive angiogenesis and colitis via TSP1/nitric oxide axis. EMBO Molecular Medicine, 2020, 12, e10862.	3.3	33
193	Eradication of <i>Helicobacter pylori</i> for the Prevention of Peptic Ulcer Rebleeding. Helicobacter, 2007, 12, 279-286.	1.6	32
194	Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple or concomitant treatment to eradicate <i>H. pylori</i> infection. Scandinavian Journal of Gastroenterology, 2013, 48, 652-656.	0.6	32
195	Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. Journal of Crohn's and Colitis, 2014, 8, 183-190.	0.6	32
196	Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. Digestive and Liver Disease, 2016, 48, 601-607.	0.4	32
197	The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma. European Journal of Gastroenterology and Hepatology, 2004, 16, 135-138.	0.8	29
198	Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: A real-life survey in Spain. Journal of Crohn's and Colitis, 2010, 4, 567-574.	0.6	29

#	ARTICLE	IF	CITATIONS
199	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 606-616.	0.9	29
200	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3533.	1.0	29
201	Pantoprazole based therapies in <i>Helicobacter pylori</i> eradication. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 89-99.	0.8	28
202	Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018, 50, 353-359.	0.4	28
203	Acute severe ulcerative colitis: State of the art treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 59-69.	1.0	28
204	Differences between childhood and adulthood onset inflammatory bowel disease: the CAROUSEL study from GETECCU. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 419-428.	1.9	28
205	Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF) Tj ETQq1 1 0.784314 rgBT /Overlock	1.0	28
206	¹³ C-urea Breath Test during Hospitalization for the Diagnosis of <i>Helicobacter pylori</i> Infection in Peptic Ulcer Bleeding. <i>Helicobacter</i> , 2007, 12, 231-237.	1.6	27
207	IV Spanish Consensus Conference on <i>Helicobacter pylori</i> infection treatment. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2016, 39, 697-721.	0.0	27
208	Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. <i>American Journal of Gastroenterology</i> , 2017, 112, 1135-1143.	0.2	27
209	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorización, prevención y tratamiento de la recurrencia posquirúrgica en la enfermedad de Crohn. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 472-483.	0.2	27
210	<i>Helicobacter pylori</i> first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on <i>Hp</i> management (HpEuReg). <i>Helicobacter</i> , 2020, 25, e12686.	1.6	27
211	Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1725-1736.	0.9	27
212	Empirical vs. Susceptibility-Guided Treatment of <i>Helicobacter pylori</i> Infection: A Systematic Review and Meta-Analysis. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	27
213	<i>Helicobacter pylori</i> 'Test-and-Treat' Strategy for Dyspeptic Patients. <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 644-652.	0.6	26
214	Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience. <i>Gastroenterología Y Hepatología</i> , 2011, 34, 443-448.	0.2	26
215	A new, single-capsule bismuth-containing quadruple therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 307-309.	8.2	26
216	High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high <i>Helicobacter pylori</i> eradication rates. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 190-196.	1.9	26

#	ARTICLE	IF	CITATIONS
217	Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3075-3084.	1.1	26
218	Treatment of <i>Helicobacter pylori</i> infection 2017. <i>Helicobacter</i> , 2017, 22, e12410.	1.6	26
219	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) y de la Confederación de Asociaciones de Enfermedad de Crohn y Colitis Ulcerosa (ACCU) para el manejo de los aspectos psicológicos en la enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> . 2018, 41, 118-127.	0.2	26
220	Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2019, 11, 2605.	1.7	26
221	Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1484-1485.	1.9	25
222	Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 657-662.	0.6	25
223	<i>Helicobacter pylori</i> "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain" Results of the HpBreath initiative. <i>Helicobacter</i> , 2020, 25, e12693.	1.6	25
224	Effectiveness of infliximab after adalimumab failure in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 5219-24.	1.4	25
225	Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review. <i>Pharmaceuticals</i> , 2021, 14, 1190.	1.7	25
226	Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. <i>Gastroenterología Y Hepatología</i> , 2008, 31, 421-426.	0.2	24
227	Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1287-1293.	0.6	24
228	Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2019, 64, 846-854.	1.1	24
229	Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for <i>Helicobacter pylori</i> Eradication: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017, 77, 765-776.	4.9	23
230	Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2017, 49, 1086-1091.	0.4	23
231	Systematic review with meta-analysis: the prevalence of bile acid malabsorption and response to colestyramine in patients with chronic watery diarrhoea and previous cholecystectomy. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 242-250.	1.9	23
232	Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 1056-1066.	1.6	23
233	Is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 17-27.	1.9	22
234	Two-week, high-dose proton pump inhibitor, moxifloxacin triple <i>Helicobacter pylori</i> therapy after failure of standard triple or non-bismuth quadruple treatments. <i>Digestive and Liver Disease</i> , 2015, 47, 108-113.	0.4	22

#	ARTICLE	IF	CITATIONS
235	Monitoring thiopurine metabolites in inflammatory bowel disease. <i>Frontline Gastroenterology</i> , 2016, 7, 301-307.	0.9	22
236	Ratio of Circulating Estrogen Receptors Beta and Alpha (ER ^β /ER ^α) Indicates Endoscopic Activity in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2744-2754.	1.1	22
237	Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. <i>United European Gastroenterology Journal</i> , 2021, 9, 766-772.	1.6	22
238	Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 379-386.	0.6	21
239	Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease. <i>Biomarkers</i> , 2017, 22, 133-144.	0.9	21
240	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterology and Hepatology</i> , 2018, 41, 389-405.	0.2	21
241	Gene expression study and pathway analysis of histological subtypes of intestinal metaplasia that progress to gastric cancer. <i>PLoS ONE</i> , 2017, 12, e0176043.	1.1	21
242	Prevalence of <i>Helicobacter pylori</i> infection in medical professionals in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 239-242.	0.8	20
243	Empirical <i>Helicobacter pylori</i> rescue therapy after failure of two eradication treatments. <i>Digestive and Liver Disease</i> , 2004, 36, 7-12.	0.4	20
244	Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 654-661.	0.6	20
245	Maintenance therapy options for ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1339-1349.	0.9	20
246	Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. <i>Gastroenterology and Hepatology</i> , 2019, 42, 403-412.	0.2	20
247	The Role of Immunomodulators and Biologics in the Medical Management of Stricture Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 557-566.	0.6	20
248	Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1380-1386.	0.6	19
249	Evaluation of 3 different tests for the detection of stool antigens to confirm <i>Helicobacter pylori</i> eradication after treatment. A pilot study. <i>Gastroenterology and Hepatology</i> , 2005, 28, 615-618.	0.2	18
250	EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984703.	1.4	18
251	Spanish primary care survey on the management of <i>Helicobacter pylori</i> infection and dyspepsia: Information, attitudes, and decisions. <i>Helicobacter</i> , 2019, 24, e12593.	1.6	18
252	Management of gastro-oesophageal reflux disease in primary care: a European observational study. <i>Current Medical Research and Opinion</i> , 2009, 25, 2777-2784.	0.9	17

#	ARTICLE	IF	CITATIONS
253	Is Culture Necessary before First-line Treatment for Helicobacter pylori Infection?. Internal Medicine, 2011, 50, 2717-2717.	0.3	17
254	Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. European Journal of Medicinal Chemistry, 2013, 68, 284-290.	2.6	17
255	Bismuth quadruple regimen with tetracycline or doxycycline versus three single capsules as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter, 2020, 25, e12722.	1.6	17
256	Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile. Mediators of Inflammation, 2015, 2015, 1-8.	1.4	16
257	Research to the N-Power: The Strengths of Networked Clinical Collaboration in Spain. American Journal of Gastroenterology, 2017, 112, 1761-1764.	0.2	16
258	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. Journal of Clinical Investigation, 2021, 131, .	3.9	16
259	Clinical outcome after anti-tumor necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1277-1288.	1.9	16
260	Probiotics for Helicobacter pylori eradication therapy: not ready for prime time. Revista Espanola De Enfermedades Digestivas, 2013, 105, 441-444.	0.1	16
261	Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment. Digestive and Liver Disease, 2017, 49, 973-977.	0.4	15
262	Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection. Gastroenterology and Hepatology, 2017, 40, 651-657.	0.2	15
263	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 1270-1279.	0.6	15
264	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology, 2022, 20, 1671-1686.e16.	2.4	15
265	Inhibition of integrin $\alpha 6 \beta 1$ sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. , 2022, 10, e003465.		15
266	Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical Gastroenterology and Hepatology, 2022, 20, 2243-2257.	2.4	15
267	La relación mentor-aprendiz en medicina. Gastroenterology and Hepatology, 2017, 40, 48-57.	0.2	14
268	Poor Sensitivity of Fecal Gluten Immunogenic Peptides and Serum Antibodies to Detect Duodenal Mucosal Damage in Celiac Disease Monitoring. Nutrients, 2021, 13, 98.	1.7	14
269	Helicobacter pylori and gastroesophageal reflux disease: friends or foes?. Hepato-Gastroenterology, 1999, 46, 1023-9.	0.5	14
270	Risk Assessment and Outpatient Management in Bleeding Peptic Ulcer. Journal of Clinical Gastroenterology, 2006, 40, 129-134.	1.1	13

#	ARTICLE	IF	CITATIONS
271	Effectiveness of anti-TNF± drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF± agent. <i>Digestive and Liver Disease</i> , 2016, 48, 613-619.	0.4	13
272	Ustekinumab en el tratamiento de la enfermedad de Crohn. <i>GastroenterologÃa Y HepatologÃa</i> , 2017, 40, 688-698.	0.2	13
273	Randomised clinical trial: intravenous vs oral iron for the treatment of anaemia after acute gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 258-268.	1.9	13
274	Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10224.	1.8	13
275	Clinical characteristics and prognostic factors for Crohnâ€™s disease relapses using natural language processing and machine learning: a pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 389-397.	0.8	13
276	Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg). <i>Journal of Clinical Medicine</i> , 2022, 11, 1658.	1.0	13
277	Adalimumab-induced interstitial pneumonia in a patient with Crohnâ€™s disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 2260-2262.	1.4	12
278	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohnâ€™s disease patients treated with infliximab. <i>Biochemical Pharmacology</i> , 2016, 122, 33-41.	2.0	12
279	Biosimilar and interchangeable: Inseparable scientific concepts?. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2460-2463.	1.1	12
280	Empirical <i>Helicobacter pylori</i> rescue therapy: an 18â€year singleâ€centre study of 1200 patients. <i>GastroHep</i> , 2019, 1, 311-324.	0.3	12
281	Optimization Strategies Aimed to Increase the Efficacy of <i>Helicobacter pylori</i> Eradication Therapies with Quinolones. <i>Molecules</i> , 2020, 25, 5084.	1.7	12
282	Tacrolimus induces shortâ€term but not longâ€term clinical response in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 870-879.	1.9	12
283	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1180-1188.e4.	2.4	12
284	Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1802-1811.	0.2	12
285	European Registry on <i>Helicobacter pylori</i> Management: Effectiveness of First and Second-Line Treatment in Spain. <i>Antibiotics</i> , 2021, 10, 13.	1.5	12
286	Gastric MALT lymphoma: clinical characteristics and prevalence of <i>H. pylori</i> infection in a series of 37 cases. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006, 98, 655-65.	0.1	12
287	Hallmarks of the human intestinal microbiome on liver maturation and function. <i>Journal of Hepatology</i> , 2022, 76, 694-725.	1.8	12
288	Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: A European observational study. <i>European Journal of General Practice</i> , 2009, 15, 154-160.	0.9	12

#	ARTICLE	IF	CITATIONS
289	7-day rescue therapy with ranitidine bismuth citrate after <i>Helicobacter pylori</i> treatment failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1249-1253.	1.9	11
290	How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1749-1762.	1.0	11
291	Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin) Tj ETQq1 1 0.784314 rgBT /Overl <i>HepatologĀa</i> , 2017, 40, 658-662.	0.2	11
292	Actualizaci3n en el manejo de la infecci3n por <i>Helicobacter pylori</i> . Documento de posicionamiento de la Societat Catalana de Digestologia. <i>GastroenterologĀa Y HepatologĀa</i> , 2018, 41, 272-280.	0.2	11
293	Recomendaciones del Grupo Espaol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 1: epidemiologĀa, diagn3stico y pron3stico. <i>GastroenterologĀa Y HepatologĀa</i> , 2019, 42, 568-578.	0.2	11
294	Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2080-2087.	1.4	11
295	Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2132.	1.0	11
296	Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2001034.	1.5	11
297	The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 17562848211018097.	1.4	11
298	Treatment of <i>Helicobacter pylori</i> infection 2016. <i>Helicobacter</i> , 2016, 21, 55-61.	1.6	10
299	Reglas y consejos para ser un investigador de 3xito. <i>GastroenterologĀa Y HepatologĀa</i> , 2020, 43, 540-550.	0.2	10
300	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. <i>Journal of Clinical Medicine</i> , 2021, 10, 4402.	1.0	10
301	<i>H. pylori</i> eradication therapy vs. antisecretory non-eradication therapy (with or without long-term) Tj ETQq1 1 0.784314 rgBT /Overl , CD004062.	0.9	9
302	Letter: are lymphocytic colitis and collagenous colitis really the same disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 606-606.	1.9	9
303	Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for <i>Helicobacter pylori</i> infection. <i>International Journal of Clinical Practice</i> , 2017, 71, e13004.	0.8	9
304	<i>Helicobacter pylori</i> treatment results in Slovenia in the period 2013-2015 as a part of European Registry on <i>Helicobacter pylori</i> Management. <i>Radiology and Oncology</i> , 2017, 52, 1-6.	0.6	9
305	Genetic variation analysis in a follow-up study of gastric cancer precursor lesions confirms the association of <i>MUC2</i> variants with the evolution of the lesions and identifies a significant association with <i>NFKB1</i> and <i>CD14</i> . <i>International Journal of Cancer</i> , 2018, 143, 2777-2786.	2.3	9
306	Manejo de la colitis ulcerosa aguda grave en Espaa: Resultados de una encuesta sobre prctica clnica. <i>GastroenterologĀa Y HepatologĀa</i> , 2019, 42, 90-101.	0.2	9

#	ARTICLE	IF	CITATIONS
307	Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract. <i>Journal of Functional Foods</i> , 2019, 52, 459-468.	1.6	9
308	Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112239.	2.5	9
309	Europeyskiy registr Helicobacter pylori (Hp-EuReg): analiz dannyykh 2360 bol'nykh, poluchavshikh terapiyu pervoy linii v Rossii. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 35-42.	0.2	9
310	Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1070-1078.	0.6	9
311	Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: A European observational study. <i>European Journal of General Practice</i> , 2009, 15, 154-160.	0.9	8
312	Outcome after a dose-intensification strategy with anti-TNF drugs in patients with Crohn's disease. <i>Gastroenterology and Hepatology</i> , 2016, 39, 255-260.	0.2	8
313	Validation of the "United Registries for Clinical Assessment and Research" [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 532-537.	0.6	8
314	The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1062-1066.	0.8	8
315	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2914.	1.0	8
316	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 421.	1.0	8
317	Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. <i>Hepato-Gastroenterology</i> , 2006, 53, 399-404.	0.5	8
318	Evaluation of Natural Language Processing for the Identification of Crohn Disease-Related Variables in Spanish Electronic Health Records: A Validation Study for the PREMONITION-CD Project. <i>JMIR Medical Informatics</i> , 2022, 10, e30345.	1.3	8
319	Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1021-1029.	1.9	8
320	Rectal hypersensitivity in patients with quiescent ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 592-592.	0.6	7
321	Eficacia y seguridad de vedolizumab en el tratamiento de la colitis ulcerosa. <i>Gastroenterology and Hepatology</i> , 2016, 39, 677-686.	0.2	7
322	Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Tj ETQq0 0 0 rgBT /Overlock 10 T 229-235.	1.6	7
323	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento. <i>Gastroenterology and Hepatology</i> , 2020, 43, 649-658.	0.2	7
324	P744 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemiIBD study of GETECCU. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S594-S597.	0.6	7

#	ARTICLE	IF	CITATIONS
325	The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory) Tj ETQq1 1 0.784314 rgBT /Overlo (English Edition), 2020, 43, 551-558.	0.0	7
326	Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective. Expert Opinion on Biological Therapy, 2022, 22, 109-121.	1.4	7
327	Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg). Journal of Clinical Medicine, 2022, 11, 3544.	1.0	7
328	Tratamiento actual de la infecci3n por Helicobacter pylori. Medicina Cl3nica, 2017, 148, 20-22.	0.3	6
329	Preguntas y errores en el diagn3stico y manejo de la anemia en pacientes con hemorragia digestiva. Gastroenterolog3a Y Hepatolog3a, 2018, 41, 63-76.	0.2	6
330	Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells. Inflammatory Intestinal Diseases, 2019, 4, 161-174.	0.8	6
331	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq1 1 0.784314 rgBT /Overlo Gastroenterolog3a Y Hepatolog3a, 2020, 43, 117-125.	0.2	6
332	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. European Journal of Gastroenterology and Hepatology, 2020, 32, 588-596.	0.8	6
333	Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study). Alimentary Pharmacology and Therapeutics, 2021, 54, 1041-1051.	1.9	6
334	The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg). Antibiotics, 2021, 10, 965.	1.5	6
335	Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry. Journal of Crohn's and Colitis, 2021, , .	0.6	6
336	Commentary: comparators in H. pylori eradication "stating the ethics of statins. Alimentary Pharmacology and Therapeutics, 2012, 36, 400-401.	1.9	5
337	Enfermedades relacionadas con la infecci3n por Helicobacter pylori. Gastroenterolog3a Y Hepatolog3a, 2016, 39, 36-46.	0.2	5
338	Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. Gastroenterolog3a Y Hepatolog3a (English Edition), 2018, 41, 63-76.	0.0	5
339	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481987420.	1.4	5
340	Helicobacter pylori eradication rates in Slovenia in the period from 2017 to 2019 " data from the European Registry on Helicobacter pylori Management (Hp-EuReg). Digestive Diseases, 2020, 39, 318-324.	0.8	5
341	A quick flow cytometry protocol to assess Helicobacter pylori viability. Journal of Microbiological Methods, 2020, 177, 106043.	0.7	5
342	Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. Journal of Crohn's and Colitis, 2020, 14, 1290-1298.	0.6	5

#	ARTICLE	IF	CITATIONS
343	Tissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1184-1200.	0.9	5
344	Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. <i>Antibiotics</i> , 2021, 10, 1028.	1.5	5
345	Retos y desafíos de la investigación científica independiente. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 599-610.	0.2	5
346	Eradication of Helicobacter pylori Infection with Non-Bismuth Quadruple Concomitant Therapy. <i>Frontiers in Anti-infective Drug Discovery</i> , 2020, , 1-34.	0.6	5
347	Reglas y consejos para ser un buen revisor por pares de manuscritos científicos. <i>Gastroenterología Y Hepatología</i> , 2023, 46, 215-235.	0.2	5
348	Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1428-1435.	0.6	5
349	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 940-945.	0.6	5
350	Towards effective empirical treatment for Helicobacter pylori eradication. <i>Lancet, The</i> , 2016, 388, 2325-2326.	6.3	4
351	Ustekinumab to treat Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017, 40, 688-698.	0.0	4
352	Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease. <i>Pharmacogenomics Journal</i> , 2019, 19, 547-555.	0.9	4
353	Follow-Up Study Confirms the Presence of Gastric Cancer DNA Methylation Hallmarks in High-Risk Precursor Lesions. <i>Cancers</i> , 2021, 13, 2760.	1.7	4
354	Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients. <i>Frontiers in Medicine</i> , 2022, 9, 823900.	1.2	4
355	Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity. <i>Biomedicines</i> , 2022, 10, 727.	1.4	4
356	Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1374-1375.	1.9	3
357	Letter: the definition of budesonide dependence in microscopic colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 635-635.	1.9	3
358	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English)</i> 10.1016/j.gtc.2022.06.006	0.0	0
359	Alertas sobre la seguridad de las quinolonas: ¿debemos modificar su prescripción en el tratamiento de la infección por Helicobacter pylori. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 461-463.	0.2	3
360	Efficacy of tofacitinib treatment in ulcerative colitis. <i>Gastroenterología Y Hepatología (English)</i> 10.1016/j.gtc.2022.06.006	0.0	0

#	ARTICLE	IF	CITATIONS
361	Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECI trial. <i>Digestive and Liver Disease</i> , 2019, 51, 529-535.	0.4	3
362	Measurement of Anti-TNF Agents and Anti-Drug Antibodies Serum Levels in Patients with Inflammatory Bowel Disease. <i>Current Drug Metabolism</i> , 2015, 15, 875-881.	0.7	3
363	Assessment of first-line eradication treatment in Greece: data from the European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg). <i>Annals of Gastroenterology</i> , 2021, 35, 42-47.	0.4	3
364	Encuesta de adherencia al tratamiento en enfermedad inflamatoria intestinal. Estudio ENADEII. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 285-292.	0.2	3
365	W1300 Effectiveness of Infliximab After Adalimumab Failure in Crohn's Disease. <i>Gastroenterology</i> , 2010, 138, S-694.	0.6	2
366	Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 940-941.	1.9	2
367	Is Less More: Does Leukopenia Predict Remission in Patients with Inflammatory Bowel Disease Receiving Thiopurine Treatment?. <i>Digestive Diseases and Sciences</i> , 2015, 60, 4-6.	1.1	2
368	Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 583-598.	0.9	2
369	Efficacy and safety of vedolizumab in the treatment of ulcerative colitis. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2016, 39, 677-686.	0.0	2
370	Letter: <i>Helicobacter pylori</i> infection and eosinophilic oesophagitis – causal or casual inverse association?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1244-1244.	1.9	2
371	Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 855-856.	1.9	2
372	Reply. <i>Gastroenterology</i> , 2017, 152, 303-304.	0.6	2
373	Enfermedad celíaca no respondedora: crisis celíaca vs. enfermedad celíaca refractaria con respuesta a corticoides. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 529-530.	0.2	2
374	Update on the management of <i>Helicobacter pylori</i> infection. Position paper from the Catalan Society of Digestology. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 272-280.	0.0	2
375	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 514-529.	0.0	2
376	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 389-405.	0.0	2
377	Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019, 42, 90-101.	0.0	2
378	Surgery for Crohn's disease during pregnancy: a difficult decision. <i>United European Gastroenterology Journal</i> , 2020, 8, 633-634.	1.6	2

#	ARTICLE	IF	CITATIONS
379	Errores en la atención de los pacientes con enfermedad inflamatoria intestinal: estudio «ERRATA». Gastroenterología Y Hepatología, 2020, 43, 233-239.	0.2	2
380	¿Cómo elaborar un proyecto de investigación en ciencias de la salud?. Gastroenterología Y Hepatología, 2021, 44, 730-740.	0.2	2
381	European Registry on Helicobacter pylori management (Hp-EuReg): First-line Therapy in Israel. Israel Medical Association Journal, 2021, 23, 38-42.	0.1	2
382	Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU. Journal of Clinical Medicine, 2022, 11, 3915.	1.0	2
383	Letter: mucosal healing in ulcerative colitis « higher relevance than in Crohn's disease?. Alimentary Pharmacology and Therapeutics, 2013, 38, 207-207.	1.9	1
384	Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided. Alimentary Pharmacology and Therapeutics, 2013, 38, 992-992.	1.9	1
385	Letter: infliximab in severe ulcerative colitis « is it useful for all patients?. Alimentary Pharmacology and Therapeutics, 2013, 38, 1413-1413.	1.9	1
386	Letter: acute severe ulcerative colitis - should all patients be treated equally?. Alimentary Pharmacology and Therapeutics, 2014, 39, 113-113.	1.9	1
387	Optimum second-line regimens for Helicobacter pylori eradication. The Cochrane Library, 2014, , .	1.5	1
388	Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second-line regimen in the presence of levofloxacin resistance - authors' reply. Alimentary Pharmacology and Therapeutics, 2015, 41, 1221-1222.	1.9	1
389	Letter: clarithromycin dose for H. pylori therapy remains unresolved. Alimentary Pharmacology and Therapeutics, 2015, 42, 631-632.	1.9	1
390	Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm. Alimentary Pharmacology and Therapeutics, 2015, 42, 942-943.	1.9	1
391	Response to. European Journal of Gastroenterology and Hepatology, 2015, 27, 105-106.	0.8	1
392	Letter: thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2015, 41, 494-495.	1.9	1
393	In H. pylori-infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal. Evidence-Based Medicine, 2016, 21, 144-144.	0.6	1
394	Últimas novedades presentadas en gastroenterología. Gastroenterología Y Hepatología, 2016, 39, 1-2.	0.2	1
395	Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab. Alimentary Pharmacology and Therapeutics, 2016, 43, 168-169.	1.9	1
396	Current treatment of Helicobacter pylori infection. Medicina Clínica (English Edition), 2017, 148, 20-22.	0.1	1

#	ARTICLE	IF	CITATIONS
397	Accuracy of the Ultra-Rapid Urease Test for diagnosis of <i>Helicobacter pylori</i> infection. <i>GastroenterologĀa Y HepatologĀa (English Edition)</i> , 2017, 40, 651-657.	0.0	1
398	P138 Prediction model to safely cease anti-TNF therapy in CrohnĀ™s disease: individual patient data meta-analysis (IPD-MA). <i>Journal of Crohn's and Colitis</i> , 2019, 13, S158-S159.	0.6	1
399	Functional rare variants influence the clinical response to anti-TNF therapy in CrohnĀ™s disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986784.	1.4	1
400	P424 Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S321-S322.	0.6	1
401	Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit. <i>ReumatologĀa ClĀnica</i> , 2019, 15, 63-68.	0.2	1
402	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2822-2823.	2.4	1
403	Recomendaciones del Grupo EspaĀol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento tĀpico en la colitis ulcerosa. <i>GastroenterologĀa Y HepatologĀa</i> , 2020, 43, 97-105.	0.2	1
404	Errors in the care of inflammatory bowel disease patients: ĀErrataĀ Study. <i>GastroenterologĀa Y HepatologĀa (English Edition)</i> , 2020, 43, 233-239.	0.0	1
405	Empirical or susceptibilityĀguided treatment of refractory <i>Helicobacter pylori</i> infection?. <i>GastroHep</i> , 2020, 2, 4-5.	0.3	1
406	Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 806-811.	0.6	1
407	Evaluation of the Effectiveness of <i>Helicobacter pylori</i> Eradication Regimens in Lithuania during the Years 2013Ā2020: Data from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg). <i>Medicina (Lithuania)</i> , 2021, 57, 642.	0.8	1
408	Derrame pericĀrdico asociado al tratamiento con mesalazina en un paciente con colitis ulcerosa. <i>GastroenterologĀa Y HepatologĀa</i> , 2020, 44, 721-723.	0.2	1
409	European Registry on the management of <i>Helicobacter pylori</i> infection (Hp-EuReg protocol): The first results of Russian Centers. <i>Russian Journal of Evidence-Based Gastroenterology</i> , 2016, 5, 9.	0.3	1
410	Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 688-693.	0.1	1
411	CaracterĀsticas epidemiolĀgicas, clĀnicas y respuesta al tratamiento en 113 pacientes con colitis microscĀpica. <i>GastroenterologĀa Y HepatologĀa</i> , 2021, 44, 671-679.	0.2	1
412	Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID). <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, e837-e842.	0.8	1
413	Attitude facing a patient suffering from <i>Helicobacter pylori</i> infection resistant to a triple therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2003, 95, 220-8, 210-19.	0.1	1
414	Letter: mucosal <sc>PCR</sc> for cytomegalovirus in refractory ulcerative colitis Ā authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 812-812.	1.9	0

#	ARTICLE	IF	CITATIONS
415	Reply to Dr. Katsanos et al.'s letter. Journal of Crohn's and Colitis, 2013, 7, e23-e24.	0.6	0
416	Editorial: quadruple therapy for <i>H. pylori</i> eradication is better than triple therapy – authors' reply. Alimentary Pharmacology and Therapeutics, 2015, 41, 695-696.	1.9	0
417	Letter: tumour necrosis factor alpha blocker switching - a not so simple pharmacokinetic. Authors' reply. Alimentary Pharmacology and Therapeutics, 2015, 41, 1302-1303.	1.9	0
418	Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure - authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 1020-1020.	1.9	0
419	Letter: anti-TNF in steroid-dependent ulcerative colitis – are the available data enough?. Alimentary Pharmacology and Therapeutics, 2016, 44, 102-102.	1.9	0
420	Letter: oral low-dose methotrexate for collagenous colitis – authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 98-98.	1.9	0
421	Ensuring the highest eradication rates in <i>H. pylori</i> : the case of non-bismuth quadruple concomitant therapy. European Journal of Internal Medicine, 2016, 33, 1-2.	1.0	0
422	Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 HepatologÅa (English Edition), 2017, 40, 658-662.	0.0	0
423	P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU. Journal of Crohn's and Colitis, 2018, 12, S174-S176.	0.6	0
424	P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. Journal of Crohn's and Colitis, 2019, 13, S328-S329.	0.6	0
425	Warnings on the safety of quinolones: Should <i>Helicobacter pylori</i> treatment prescriptions be modified?. GastroenterologÅa Y HepatologÅa (English Edition), 2019, 42, 461-463.	0.0	0
426	DOP44 Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU. Journal of Crohn's and Colitis, 2019, 13, S052-S053.	0.6	0
427	P526 Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY. Journal of Crohn's and Colitis, 2019, 13, S376-S376.	0.6	0
428	P816 Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. Journal of Crohn's and Colitis, 2019, 13, S529-S531.	0.6	0
429	P223 Efficacy and safety of tacrolimus in Crohn's disease: a nationwide, multi-centric study from GETECCU. Journal of Crohn's and Colitis, 2019, 13, S207-S208.	0.6	0
430	P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab. Journal of Crohn's and Colitis, 2019, 13, S410-S410.	0.6	0
431	P013 Novel immunomodulatory role of food bioactive peptide lunasin in the healthy human intestinal mucosa. Journal of Crohn's and Colitis, 2019, 13, S092-S093.	0.6	0
432	Response to the Letter to the Editor: – Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease – Inflammatory Bowel Diseases, 2019, 26, e6.	0.9	0

#	ARTICLE	IF	CITATIONS
433	Are there reliable predictive factors of nonresponse to aminosalicylates in patients with ulcerative colitis?. United European Gastroenterology Journal, 2019, 7, 997-998.	1.6	0
434	P040 Proteomic characterisation of serum extracellular vesicles in patients with inflammatory bowel diseases: a novel approach for biomarker discovery. Journal of Crohn's and Colitis, 2020, 14, S152-S153.	0.6	0
435	P086 Identification of constitutive modifications in plasma cells and B lymphocytes in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2020, 14, S177-S178.	0.6	0
436	P475 Association between disease duration and degree of endoscopic improvement in patients with ulcerative colitis treated with tofacitinib. Journal of Crohn's and Colitis, 2020, 14, S416-S418.	0.6	0
437	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. Gastroenterology & Hepatology (English Edition), 2020, 43, 79-86.	0.0	0
438	P573 Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: an on-going systematic review with meta-analysis. Journal of Crohn's and Colitis, 2020, 14, S482-S483.	0.6	0
439	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq1 1 0.784314 rgBT /Overlook Gastroenterology & Hepatology (English Edition), 2020, 43, 117-125.	0.0	0
440	P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study. Journal of Crohn's and Colitis, 2020, 14, S359-S360.	0.6	0
441	DOP19 Urinary metabolome in newly diagnosed treatment-naïve Crohn's Disease patients: Results from the IBDomics study. Journal of Crohn's and Colitis, 2021, 15, S057-S058.	0.6	0
442	Editorial: withdrawal of anti-TNFalpha—are we ready for biological therapy cycling? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 86-87.	1.9	0
443	Challenges of independent clinical research. Gastroenterology & Hepatology (English Edition), 2021, 44, 599-599.	0.0	0
444	V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterology & Hepatology (English Edition), 2021, , .	0.0	0
445	How to prepare a research proposal in the health sciences. Gastroenterology & Hepatology (English) Tj ETQq1 1 0.784314 rgBT /Overlook	0.0	0
446	Ausencia de interferencia de almagato en los resultados de la prueba de aliento para el diagnóstico de Helicobacter pylori (estudio Almatest). Gastroenterology & Hepatology, 2021, 44, 628-636.	0.2	0
447	P128 Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real life experience. Journal of Crohn's and Colitis, 2020, 14, S201-S201.	0.6	0
448	Epidemiological and clinical characteristics, and response to treatment in 113 patients with microscopic colitis. Gastroenterology & Hepatology (English Edition), 2021, 44, 671-671.	0.0	0
449	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. Gastroenterology & Hepatology, 2020, 43, 79-86.	0.2	0